De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Anika Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Anika Therapeutics is gedaald met een gemiddeld jaarlijks percentage van -68.7%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19.7%. De inkomsten zijn groeide met een gemiddeld percentage van 8.6% per jaar.

Belangrijke informatie

-68.7%

Groei van de winst

-68.4%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	8.6%
Rendement op eigen vermogen	-35.3%
Nettomarge	-44.4%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Jan 30

Anika Therapeutics (ANIK) Presents At UBS Global Healthcare Virtual Conference - Slideshow

May 28

Anika Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

Mar 16

Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly

Feb 09

An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued

Jan 13

If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%

Dec 18

Anika Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Opbrengsten en kosten

Hoe Anika Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:ANIK Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	167	-74	73	31
31 Mar 24	169	-77	82	32
31 Dec 23	167	-83	83	33
30 Sep 23	163	-25	99	33
30 Jun 23	162	-22	95	32
31 Mar 23	157	-22	93	30
31 Dec 22	156	-15	85	28
30 Sep 22	152	-16	82	26
30 Jun 22	152	-11	78	26
31 Mar 22	150	-2	75	27
31 Dec 21	148	4	74	27
30 Sep 21	145	-6	70	28
30 Jun 21	137	-13	69	25
31 Mar 21	129	-27	63	22
31 Dec 20	130	-24	57	22
30 Sep 20	128	-4	50	20
30 Jun 20	126	11	40	19
31 Mar 20	125	28	36	18
31 Dec 19	115	27	35	17
30 Sep 19	112	31	31	17
30 Jun 19	109	29	27	17
31 Mar 19	109	30	26	17
31 Dec 18	106	19	28	18
30 Sep 18	108	19	27	18
30 Jun 18	108	18	28	20
31 Mar 18	111	20	26	20
31 Dec 17	113	32	22	19
30 Sep 17	113	32	20	17
30 Jun 17	111	34	20	14
31 Mar 17	104	31	19	13
31 Dec 16	103	33	18	11
30 Sep 16	106	36	17	10
30 Jun 16	103	35	16	9
31 Mar 16	100	34	15	8
31 Dec 15	93	31	15	8
30 Sep 15	85	28	14	8
30 Jun 15	84	25	15	8
31 Mar 15	87	27	15	8
31 Dec 14	106	38	15	8
30 Sep 14	104	37	14	8
30 Jun 14	99	36	13	8
31 Mar 14	94	33	12	8
31 Dec 13	75	21	13	7

Kwaliteitswinsten: ANIK is momenteel verliesgevend.

Groeiende winstmarge: ANIK is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: ANIK is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 68.7% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van ANIK over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: ANIK is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 0.5% ).

Rendement op eigen vermogen

Hoge ROE: ANIK heeft een negatief Return on Equity ( -35.27% ), omdat het momenteel verliesgevend is.

Anika Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Anika Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Anika Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Anika Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Price target increased by 14% to US$34.50

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Anika Therapeutics, Inc. Affirms Earnings Guidance for the Fiscal Year 2024

Anika Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Anika Therapeutics, Inc. Announces Full Market Release of the Integrity Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs

Anika Therapeutics, Inc., Annual General Meeting, Jul 09, 2024

Anika Therapeutics, Inc. (NasdaqGS:ANIK) announces an Equity Buyback for $40 million worth of its shares.

Anika Therapeutics, Inc. Announces Board Changes

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Anika Therapeutics, Inc. Announces CFO Changes

Anika Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

President exercised options and sold US$717k worth of stock

Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Anika Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Anika Therapeutics, Inc. Announces First Surgeries Performed Using the Integrity Implant System

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023

Anika Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Anika Therapeutics, Inc. Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023

Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth

Anika Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Anika Therapeutics, Inc. announces Completed Enrollment of the Pivotal Phase III Clinical Study for Hyalofast (Hyalofast 15-01) on Its Path to Achieving FDA Approval in the United States

Consensus EPS estimates fall by 39%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2023

President exercised options and sold US$345k worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Anika Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2022

Anika Therapeutics, Inc.’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study

Anika Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Anika Announces First Surgeries Performed Using the X-Twist Fixation System and Commences Limited Market Release

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Anika Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Anika Receives FDA 510(k) Clearance for the X-Twist Knotless Fixation System, Expanding its Sports Medicine Soft Tissue Portfolio

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Anika Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

Price target decreased to US$40.50

Anika Therapeutics, Inc. to Report Q1, 2022 Results on May 05, 2022

President recently bought US$207k worth of stock

Anika Therapeutics: New Share Price Low May Imply New Upside Opportunity

Anika Therapeutics, Inc. Provides Revenue Guidance for Fiscal 2022

Price target decreased to US$43.75

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider exercised options and sold US$55k worth of stock

Anika Therapeutics, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Third quarter 2021 earnings released: EPS US$0.039 (vs US$0.45 loss in 3Q 2020)

Anika Therapeutics, Inc. Receives an Additional 510(K) Clearance by the Fda for Tactoset® Injectable Bone Substitute

Second quarter 2021 earnings released: EPS US$0.45 (vs US$0.54 loss in 2Q 2020)

Anika Therapeutics, Inc. Revises Earnings Guidance for the Year 2021

Anika Therapeutics, Inc. Announces First Anika Wristmotion Total Wrist Arthroplasty Surgery Performed

Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?

Independent Director Joseph Bower has left the company

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2021

Anika Therapeutics (ANIK) Presents At UBS Global Healthcare Virtual Conference - Slideshow

Independent Director recently sold US$85k worth of stock

First quarter 2021 earnings released: EPS US$0.20 (vs US$0.41 in 1Q 2020)

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2021

Anika Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

Full year 2020 earnings released: US$1.69 loss per share (vs US$1.93 profit in FY 2019)

Earnings beat expectations, revenue disappoints

Insider exercised options and sold US$64k worth of stock

New 90-day low: US$35.54

Anika Therapeutics, Inc. to Report Q4, 2020 Results on Mar 04, 2021